Sign in Subscribe
Software industry

Agilent Technologies Introduces SurePrint G3 CGH+SNP Cancer Catalog Microarrays

Strategic Insights

— 1 min read

Agilent Technologies has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, designed to detect both copy number and copy-neutral aberrations in cancer tissue samples. The new release is accompanied by the Agilent CytoGenomics 2.0 software, which supports CGH+SNP analysis of genetically complex samples. The microarrays are based on designs by the Cancer Cytogenomics Microarray Consortium and join Agilent's market-leading CGH+SNP microarrays and ISCA arrays for cytogenetic research.

Key Takeaways:

  • Agilent Technologies has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the need to detect copy number and copy-neutral aberrations in cancer tissue samples.
  • The new microarrays are based on designs by the Cancer Cytogenomics Microarray Consortium and join Agilent's market-leading CGH+SNP microarrays and ISCA arrays for cytogenetic research.
  • The Agilent CytoGenomics 2.0 software now includes support for CGH+SNP analysis of genetically complex samples, including hematological cancer samples.
  • The new microarrays are designed to detect approximately 5-Mb LOH resolution, increasing the confidence of detecting low-level mosaicism and determining the ploidy status of the cancer genome.
  • The allelic information afforded by SNP probes can help to distinguish true high hyperdiploidy from duplication of hypodiploidy, providing insight into the disease evolution.
  • The Agilent eArray online design tool allows customers to choose from 65,000 SNPs and more than 28 million prequalified CGH probes for customization of SurePrint G3 CGH+SNP cancer arrays.
  • Agilent offers a comprehensive genomics workflow solution, including the Bravo automated liquid-handling platform, Reagents, and bioinformatics software.
  • The CytoGenomics 2.0 software is available at no charge to array customers, designed to analyze data from the SurePrint CGH+SNP cancer microarray experiments.

Statistics:

  • Agilent Technologies offers approximately 65,000 SNPs and more than 28 million prequalified CGH probes for customization of SurePrint G3 CGH+SNP cancer arrays.
  • The new microarrays detect approximately 5-Mb LOH resolution, increasing the confidence of detecting low-level mosaicism and determining the ploidy status of the cancer genome.
  • Agilent offers a comprehensive genomics workflow solution, including the Bravo automated liquid-handling platform, Reagents, and bioinformatics software.

Sources:

  • Agilent Technologies (http://www.agilent.com/genomics/cgh_snp)
  • Cancer Cytogenomics Microarray Consortium (http://www.agilent.com/home/leaving.html?http://www.urmc.rochester.edu/ccmc/)
  • Marilyn M. Li, M.D., professor of molecular and human genetics, Baylor College of Medicine
  • Kathleen Shelton, Agilent senior marketing director, Genomics

Read more